AstraZeneca (NYSE: AZN) reported that its investigational drug tozorakimab significantly reduced moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations in two replicate Phase III trials.

The OBERON and TITANIA trials demonstrated a 29% reduction in exacerbations among former smokers in the OBERON study and a 34% reduction in the TITANIA study. In the overall population of current and former smokers, the reduction was 30% in OBERON and 29% in TITANIA compared with placebo, while patients remained on standard inhaled care.

Efficacy Across Patient Subgroups

The pooled analysis of both trials revealed consistent efficacy across different baseline blood eosinophil counts (BEC), a key biomarker for COPD inflammation.

Tozorakimab is the first biologic to show statistically significant efficacy in patients with low eosinophil counts (below 150 cells/uL), expanding the potential addressable patient population beyond those with high eosinophilic inflammation.

What the Numbers Show

The data indicates a dose-response relationship between baseline inflammation and treatment benefit. Patients with higher baseline BEC (≥300) experienced nearly double the relative reduction in exacerbations (43%) compared to those with lower counts (<150, 23%). However, the statistically significant result in the low-eosinophil group suggests the drug’s mechanism—targeting interleukin-33 (IL-33) signaling—addresses inflammatory pathways independent of traditional eosinophil-driven models.

Regulatory Status and Safety

The US Food and Drug Administration has accepted the Biologics License Application for tozorakimab under Priority Review. The Prescription Drug User Fee Act date is anticipated in the first quarter of 2027, following the use of a Priority Review voucher. The drug is also under regulatory review in the EU and China.

Safety profiles were favorable, with injection-site reactions being the only reported adverse drug reaction. Additionally, an integrated analysis presented at the European Respiratory Society Congress 2026 showed tozorakimab reduced mucus plug scores, an emerging outcome measure linked to worse COPD prognosis.

Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, stated the results set a new standard for COPD treatment outcomes in a broad population.

AstraZeneca (NYSE: AZN) secured US Food and Drug Administration (FDA) accelerated approval for ETCAMAH (camizestrant) in combination with a CDK4/6 inhibitor. The treatment targets adult patients with hormone receptor-positive, HER2-negative advanced breast cancer upon detection of ESR1 mutations.

The approval marks the company’s tenth FDA grant this year and its fourth in breast cancer. It is based on the pivotal SERENA-6 Phase III trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. A companion diagnostic test to detect emerging ESR1 resistance mutations in circulating tumor DNA was also approved concurrently.

Trial Efficacy and Safety

In the planned interim analysis of the SERENA-6 trial, the combination reduced the risk of disease progression or death by 56% versus standard-of-care treatment with an aromatase inhibitor and a CDK4/6 inhibitor. The hazard ratio was 0.44 (95% CI: 0.31-0.60; p<0.00001), with median progression-free survival (PFS) of 16.0 months compared to 9.2 months.

Subsequent pre-planned analysis demonstrated a statistically significant benefit in time to second disease progression (PFS2), showing 25.7 months versus 19.1 months (HR: 0.63; p=0.00373). Overall survival data remained immature but continued to mature in favor of the combination (HR: 0.87).

The safety profile was consistent with known profiles of each medicine, with no new concerns identified. Discontinuations were very low and similar across arms. Common adverse reactions included decreased neutrophils (68%) and leukocytes (66%).

Clinical Context

Approximately 30% of patients with endocrine-sensitive HR-positive disease develop ESR1 mutations during first-line treatment before disease progression. These mutations are a key driver of endocrine resistance and are associated with poor outcomes. The trial design used ctDNA monitoring via blood tests every two to three months to identify patients for early therapy switches.

What the Numbers Show

The 56% reduction in progression or death risk translates to a 6.8-month extension in median progression-free survival (16.0 months vs 9.2 months). This magnitude of improvement suggests that detecting ESR1 mutations via ctDNA before radiographic progression allows for earlier intervention, potentially delaying the onset of more aggressive disease states where treatment options are limited.

ETCAMAH is approved in more than 30 countries, including the EU, Japan, Canada, and the UK. Continued US approval may be contingent upon verification of clinical benefit in confirmatory trials.